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ABSTRACT

ISOLATION AND CHARACTERIZATION OF HUMAN T-CELL LYMPHOTROPIC
VIRUS TYPE-1 FROM PATIENTS WITH TROPICAL SPASTIC PARAPARESIS.
Guy M. McKhann II and Clarence J. Gibbs Jr., Laboratory of Central Nervous
System Studies, National Institutes of Health, Bethesda, MD. (Sponsored by G.
D. Edith Hsiung, Department of Laboratory Medicine, Yale University).

Endemic tropical spastic paraparesis/HTLV-l associated myelopathy
(TSP/HAM) is a slowly progressive chronic neurological disorder that is
manifested clinically by spastic paraparesis frequently in association with bowel
and bladder dysfunction. It is one of the most common chronic neurologic
disorders in many endemic foci around the world. Human T-lymphotropic virus
type-1 (HTLV-I) has been etiologically associated with TSP/HAM based primarily
on the high prevalence of antibodies to HTLV-I in the serum and CSF of
affected patients. We report here the isolation of HTLV-I from peripheral blood
lymphocytes and cerebrospinal fluid derived mononuclear cells of TSP/HAM
patients by stimulation with interleukin-2 and cocultivation with umbilical cord
blood mononuclear cells. Established cell lines contained HTLV-I antigen as
demonstrated by immunoflourescence and cell-associated virus particles as
observed by electron microscopy; low level reverse transcriptase activity was
detected in cultures expressing viral antigens. Virus infected cultures were
transformed in vitro as determined by their loss of contact inhibition and their
continuous growth in the absence of exogenous IL-2. Of particular significance
was our isolation of HTLV-I from three family members with TSP/HAM of varying
duration and clinical severity.
This study resulted in the first isolation of virus from a cluster of

TSP/HAM patients within the same family, the first isolation of virus from a
childhood case of TSP/HAM, and the first in vitro transformed HTLV-l-infected
cells from TSP/HAM patients. In addition, the methodology applied in this
investigation subsequently has been used to consistently isolate virus from
HTLV-I infected persons from widely separated geographic locations. This work
supports a causative role for HTLV-I in the pathogenesis of TSP/HAM and helps
to extend the spectrum of disease that may result from HTLV-I infection.
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INTRODUCTION
Endemic tropical spastic paraparesis (TSP) is the most common chronic
neurological disorder in many tropical and subtropical regions of the world
[Rodgers-Johnson et al, 1989b]. This disorder is characterized by slowly
progressive spastic paraparesis frequently in association with bowel and
bladder dysfunction. It occurs in geographically widely separated endemic foci
[Roman, 1987]. A number of processes have been postulated to be involved in
the pathogenesis of TSP in individual endemic areas including nutritional
deficiencies [Cosnett, 1965; Grieve et al, 1967], neurotoxic ingestions
[Cruickshank, 1956], and a variety of microbial infections [Minchin, 1940;
Rodgers, 1965; Robertson and Cruickshank, 1972; Roman et al, 1987]. None of
these hypotheses has been able to account for the disease in all of the
geographic foci in which it occurs [Roman et al, 1985b].
Over the past five years, it has been established that TSP patients have a
high prevalence of antibodies to human T-lymphotropic virus type-1 (HTLV-I) in
both serum and cerebrospinal fluid (CSF) [Rodgers-Johnson et al, 1988b]. This
important finding is the one piece of etiologic evidence that unifies the varied
patient populations with endemic TSP [Rodgers-Johnson et al, 1985].
Additionally, patients from nontropical southern Japan with a chronic
neurological disorder that is clinically and histopathologically indistinguishable
from TSP also have antibodies to HTLV-I in their serum and CSF [Osame et al,
1986a]. This syndrome, HTLV-I associated myelopathy (HAM), is now felt to be
identical to TSP [Roman and Osame, 1988]. Together, these chronic
encephalomyeloneuropathies are designated TSP/HAM and have been found
in more than 40 countries [Rodgers-Johnson et al, 1990].
HTLV-I, the first retrovirus isolated from humans [Poiesz et al, 1980a],
was previously implicated as the causative agent of adult T-cell leukemia (ATL)
[Yoshida et al, 1984; Gallo, 1985]. It had never been linked to neurologic
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disease until its serologic association with TSP/HAM was demonstrated.
At the time this project was initiated, serologic evidence strongly
associated HTLV-I with TSP/HAM. Virus isolation was an essential step in
establishing an etiologic role for HTLV-I in the pathogenesis of TSP/HAM.
However, isolation of virus from patients with this disease was previously
reported to be difficult, and only individual case reports of successful isolation
existed [Hirose et al, 1986; Defreitas et al, 1987; Rodgers-Johnson, 1988].
The purpose of this investigation was to isolate HTLV-I from peripheral
blood lymphocytes and mononuclear cells of the CSF of TSP/HAM patients.
Utilizing techniques similar to those that were previously successful in isolating
HTLV-I from ATL patients, isolation was accomplished through cocultivation of
patient cells with umbilical cord blood lymphocytes in the presence of
interleukin-2. This study proved to be especially significant in that it led to the
isolation of HTLV-I from three family members living in the endemic TSP focus
of Tumaco, Colombia with spastic paraparesis of varying duration and severity.
Successful isolation of the virus from the 13-year-old son represents the
youngest TSP/HAM patient isolation to date. The techniques used in this
investigation have subsequently been applied to allow consistent isolation of
virus from HTLV-I infected persons.

Nomenclature
The nomenclature of chronic tropical neurological disorders of uncertain
etiology is confusing and requires explanation. These disorders

have been

reported under various designations for the past 100 years but are now divided
into two clinical groups. Tropical ataxic neuropathy (TAN) is an endemic form of
disease manifested by predominately proprioceptive dysfunction with variable
mild pyramidal signs and optic and auditory nerve involvement. Tropical spastic
paraparesis (TSP) occurs in two forms, epidemic and endemic. Both epidemic
and endemic TSP present clinically as a predominately spastic disorder with
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frequent bowel and bladder dysfunction and variable posterior column and
spinothalamic tract involvement [Rodgers-Johnson, 1988]. HTLV-I associated
myelopathy (HAM) is a disorder that is endemic in non-tropical regions of Japan
and is identical to the endemic form of TSP [Roman and Osame, 1988].
The terms chronic HTLV-I myelitis [Roman, 1989] and HTLV-I
encephalomyeloneuropathy [Rodgers-Johnson et al, 1989] have recently been
suggested to incorporate TSP and HAM under the same heading. However, the
World Health Organization currently recognizes TSP/HAM as the official
nomenclature for this disease process, and it is this designation that is used
throughout the thesis.

Historical background
Chronic tropical neurological disorders of uncertain etiology were first
reported over one hundred years ago by Strachan who described 510
Jamaicans with "a form of multiple neuritis prevalent in the West Indies"
[Strachan, 1888; Strachan, 1897]. These patients had combined sensorimotor
findings predominated by burning pain of the soles of the feet, ataxic gait,
impaired lower extremity proprioception, and decreased or absent knee jerk
reflexes. Strachan believed malaria to be responsible [Strachan, 1888], but the
clinical picture was also compatible with arsenic intoxication from agricultural
pesticides [Heyman et al, 1956]. These cases were reviewed twenty years later
by Scott, and he concluded that a variety of clinical entities were involved
including beri-beri, pellagra, and "Jamaican peripheral neuritis" [Scott, 1918].
In 1918, Scott described an acute outbreak of "central neuritis" in 21
Jamaican sugar cane cutters whose clinical picture was similar to Strachan's
patients. Although he felt that his patients represented an acute form of
Strachan's syndrome resulting from toxic ingestion, the acute clinical
presentation suggested a postviral acute sensory neuronopathy syndrome
[Sterman et al, 1980; Roman et al, 1985b]. The first detailed autopsies were
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performed on two of Scott’s patients who died with terminal diarrhea. The
pathologic report detailed widespread changes consisting of diffuse spinal cord
fatty degeneration and fibrosis that was most marked in the posterior columns
and cerebellar tracts, extensive dorsal root ganglion fatty deposition and
pigmentation, and optic greater than auditory nerve involvement [Scott, 1918].
Since these initial two reports, hundreds of cases of unusual chronic
tropical neurologic disorders (later designated tropical myeloneuropathies
[Roman,

1985b]) with similar clinical manifestations were described

predominantly in underdeveloped areas of Africa [Wright, 1928; Stannus, 1930]
and World War II prisoners [Cruickshank, 1946; Gibberd, 1980; Gill and Bell,
1982] These reports causally implicated vitamin deficiencies [Wright, 1928;
Wright, 1936], malnutrition [Walters, 1947; Money, 1959], and/or tropica!
malabsorption (tropical sprue) [Keele et al, 1946; Elder, 1947]. Some
investigators suggested that toxic ingestion or exposure was responsible
[Cruickshank, 1946].
A clinical classification of this group of disorders was finally made in
1956 by Cruickshank who reported on 100 Jamaican patients seen at the
University of West Indies over a three year period. He detailed two clinical
pictures: 80% of his patients had predominantly lower limb spasticity and
weakness while 20% were characterized by lower limb ataxia [Cruickshank,
1956]. Cruickshank's observations paved the way for the division of tropical
myeloneuropathies into tropical ataxic neuropathy (TAN) and the two forms of
tropical spastic paraparesis (TSP), epidemic and endemic.

Tropical Ataxic Neuropathy
TAN, a term coined by Osuntokun [Osuntokun, 1968], is an endemic form
of myeloneuropathy most prevalent in parts of Africa. Patients typically complain
of "burning feet" or other lower extremity paresthesias or dysesthesias and on
examination are found to have severe impairment of position, vibration, touch,

5

and pressure sensation that is more pronounced in the distal lower extremities.
Ankle and knee jerk reflexes are diminished or absent. Mild pyramidal signs
and optic and auditory nerve involvement are sometimes present [Roman et al,
1985b]. The etiology of TAN in certain foci remains unclear, but in Nigeria and
other parts of Africa, TAN has been clearly demonstrated to result from ingestion
of improperly prepared or immature cassava root at times of food shortage.
Cassava, a root vegetable that exists in two forms, Manioc utilissima and
Manioc palmata. is the dietary staple in these regions. Improperly prepared or
immature cassava contains high levels of cyanogenic glucosides, consumption
of which results in TAN [Osuntokun, 1985; Cliff et al, 1985].

Epidemic Tropical Spastic Paraparesis
In contrast to the proprioceptive dysfunction with sensory ataxia that
predominates in TAN, lower limb spastic paraparesis with weakness and
hyperreflexia is characteristic of endemic and epidemic TSP. Epidemic TSP,
which has only been reported from Africa, presents with the rapid onset of
bilateral spastic paraparesis, sometimes in association with visual disturbance
and speech disorders. Like TAN, epidemic TSP usually results from
consumption of undercooked or poorly prepared cassava at times of drought
[Casadei et al, 1984], although an infectious agent is still thought to be the
cause in Zaire [Carton et al, 1986].

Endemic Tropical Spastic Paraparesis
Epidemiology
Following the initial description of Jamaican neuropathy by Cruickshank
[Cruikshank, 1956], endemic foci of TSP were reported in various parts of the
world under geographically specific designations including South African
paraplegia [Cosnett, 1965], Seychelles paraplegia [Roman et al, 1987a; Roman
et al, 1987b], South Indian paraplegia [Mani et al, 1969], and 'paraparesis
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espastico del Pacifico' in

Colombia [Zaninovic et al, 1981].

Additionally,

Osame described clinically similar HAM patients from temperate regions of
southern Japan [Osame et al, 1986a; Osame et al, 1987a].

It was initially

thought that HAM and TSP were different disorders and that TSP was confined
to tropical regions of the world, but it is now clear that TSP is found in some
nontropical areas (Figure 1) [Rodgers-Johnson et al, 1989] and that TSP and
HAM are the same disease [Roman and Osame, 1988].
Consistent with the population distribution of the endemic foci, most TSP
patients are black and from lower socioeconomic groups in tropical regions
[Rodgers-Johnson et al, 1990]. However, the ethnic, socioeconomic, and
geographic distributions of the disease were expanded when it was realized
that TSP and HAM are the same disease and that TSP is not restricted to
tropical regions. In addition to Japanese and blacks in endemic regions, the
disease has been reported in Indians, Chinese, mulattoes, and Caucasians
[Roman, 1987], in Caribbean migrants to the United States [Bhagavati et al,
1988] and the United Kingdom [Cruickshank et al, 1989], and also in blacks in
the United States who have never travelled to endemic areas [Bhagavati et al,
1988]. A non-tropical endemic foci of TSP/HAM has been recognized in Chile
[Cartier-Rovirosa et al, 1989], and the disorder has been reported in upper and
middle class Caucasians in the desert climate of Lima, Peru [Johnson et al,
1988]. Isolated cases have been reported in southern Italy [Annunziata et al,
1988] and France [Gessain et al, 1988].
The age of onset of TSP/HAM is usually from 35-49 years, although
patients have been less than 20 years and over 70 years at the time of
diagnosis. A few childhood cases have been reported from Japan, and a
13-year-old Colombian boy with early clinical signs and antibodies to HTLV-I in
both serum and CSF was reported as part of this study [McKhann et al, 1989].
There is a female preponderance of approximately 3 to 1 in the majority
of endemic areas, possibly because sexual transmission is predominately

unidirectional from males to females [Kajiyama et al, 1986]. Some earlier
smaller studies of the same populations reported equal sex incidence
[Montgomery and Cruickshank, 1964; Roman et al, 1987b, Rodgers-Johnson,
1990].
The prevalence of the disease varies somewhat between endemic foci
from about 50 per 100,000 in the northern Atlantic region of Martinique to 128
per 100,000 in the Seychelles Islands. In Tumaco, Colombia the prevalence for
the total population is 91 per 100,000 but increases to 281 per 100,000 if only
those older than 25 are considered. These significant prevalence rates are
comparable to the highest known prevalence of multiple sclerosis of 128 per
100,000 in the Orkney and Shetland Islands of Scotland [Roman, 1988].

Clinical Characteristics of TSP/HAM
Although there is variability, the predominant clinical features of
TSP/HAM worldwide include the gradual onset of lower extremity weakness
frequently in association with sensory symptoms ranging from burning to
numbness to pins and needles [Rodgers-Johnson et al, 1989a]. Lumbosacral
pain and urinary symptoms including frequency, urgency, nocturia, and
incontinence are common; impotence, decreased libido, and constipation also
occur frequently [Cruickshank, 1956; Montgomery and Cruickshank, 1964;
Vernant et al, 1987]. Other variable manifestations include decreased hearing
or vision and unsteadiness of gait.
On examination, patients have a spastic paraparesis with lower
extremity hyperreflexia and a spastic gait. The spastic paraparesis usually
develops insidiously and may be initially unilateral. Most patients have extensor
plantar responses, bilateral clonus, and upper extremity hyperreflexia, but less
than 50% of patients have arm weakness. Vibration sense is diminished slightly
more frequently than position sense, and peripheral sensory changes including
a sensory level or signs consistent with a root lesion may occur [Osame et al,
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1987b; Rodgers-Johnson et al, 1988a; Said et al, 1988]. Other variable signs
include diminished abdominal reflexes, nystagmus, intention tremor, optic
atrophy, nerve deafness, ptosis, recurrent laryngeal nerve palsy, and facial
weakness. Cognitive functions are preserved [Montgomery and Cruickshank,
1964; Rodgers, 1965; Zaninovic, 1988] (Table 1).
The characteristic clinical course of TSP is a slow progression over months
to years, often with periods of plateau for several years. Severe disability
usually results with 90% of patients requiring assistance to walk and 50% of
patients wheelchair bound at 10 years [Cruickshank, 1989]. Patients have
survived for up to 55 years after diagnosis [Osame et al, 1987b]. However, acute
events similar to transverse myelopathy or vascular events have been reported.
Prognosis is worse in those who become rapidly paraplegic because of
predisposition to urinary tract infections or pulmonary emboli [Rodgers, 1965].

Pathology
There have been remarkably few postmortem studies of TSP/HAM
patients. Nevertheless, pathologic findings were consistent in an early series of
15 Jamaican cases [Robertson and Cruickshank, 1972], a later report of 2
Jamaican cases [Piccardo et al, 1988], in single autopsies from the Seychelles
[Roman et al, 1987a] and South India [Mani et al, 1941], and

in Japanese

reports [Akizuki et al, 1987; Nakazato et al, 1987]. The typical pathologic
features consist of widespread meningoencephalomyelitis and spinal cord
demyelination. The meningoencephalomyelitic changes, which are greatest at
the spinal cord level, consist of perivascular inflammatory cuffing with plasma
cells, lymphocytes, and histiocytes; microvascular proliferation; reactive
astrocytic gliosis; and perivascular fibrosis with small vessel hyalinization. The
spinal cord demyelination usually affects the lateral columns more than the
posterior columns (Figure 2). In an early report on pathology, Robertson and
Cruickshank commented on the similarity of the widespread central nervous
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system disease in TSP/HAM to meningovascular syphilis. However, endarteritis
obliterans, miliary gummata and other pathologic features characteristic of
syphilis were never seen [Robertson and Cruickshank, 1972]. In patients with
long term progressive TSP/HAM [Roman, 1988], the spinal cord pathology may
resemble the vacuolar myelopathy seen in patients with the acquired
immunodeficiency syndrome [Petito et al, 1985].

Laboratory Investigations and Diagnostic Tests
Most routine laboratory tests are normal in TSP/HAM including blood and
urine chemistries, erythrocyte sedimentation rate, vitamin B12 level, and
nutritional and metabolic parameters. Peripheral blood smears can be helpful in
that 1-3% of lymphocytes may be atypical with convoluted rosette type nuclei
[Rudge, 1989]. CSF parameters are frequently normal although a moderate
predominately lymphocytic CSF leucocytosis with increased protein has been
seen in 16-57% of patients [Rodgers, 1965; Vernant et al, 1987]. Atypical
lymphocytes similar to those seen in peripheral smears are sometimes found in
the CSF [Osame et al, 1986; Osame et al, 1987b]. CSF gamma globulin is
frequently increased, and oligoclonal bands are seen [Roman, 1988].
Visual evoked potential studies are abnormal in up to 50% of patients
[Cruickshank et al, 1989], although much lower frequencies have been reported
[Bhagavati et al, 1988]. The marked symmetry of these latencies suggests that
multiple small demyelinating lesions are present within both optic nerves, a
finding that has been previously described in pathologic specimens. Minor
brain stem auditory evoked potential abnormalities are commonly seen
consisting of prolongation of various brainstem components with a normal
component 1. Somatosensory evoked potentials are usually abnormal in testing
of both the upper and lower extremities in a pattern that suggests bilateral
involvement of the fasciculus gracilis [Cruickshank et al, 1989]. Although not a
consistent finding in all studies, abnormal conduction velocities along sural and
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peroneal nerves have been reported. These abnormal F wave latencies are
most compatible with patchy demyelination/remyelination of peripheral nerves
resulting from vasculitis along the vasa nervosum [Said et al, 1988].
Magnetic resonance imaging of patients, in comparison to appropriately
age matched controls, has detected both cerebral and spinal cord lesions
[Furukawa et al, 1989]. In the brain, minor periventricular and supratentorial
white matter abnormalities are seen, occasionally accompanied by posterior
fossa lesions. These brain lesions are usually less extensive than those seen in
multiple sclerosis (MS) patients with a corresponding level of clinical disability
[Cruickshank et al, 1989]. Results of magnetic resonance imaging (MRI) must be
interpreted in relation to age because white matter abnormalities are found in
over 30% of apparently normal individuals over 50 years [Brant-Zawadski et al,
1984]. Spinal cord change visualized by MRI, if present, is limited to dorsal
column atrophy. Areas of increased signal in the spinal cord, as are sometimes
found in MS, are not seen in TSP/HAM [Rudge, 1989].

Etiology
Early studies in Jamaica [Cruickshank et al, 1961; Rodgers, 1965] and
South India [Mani et al, 1969] and more recent case control studies from
Colombia [Roman et al, 1985 ] and the Seychelles [Roman et al, 1987a] failed
to implicate diet, nutritional defiencies, neurotoxin exposure, housing,
occupation, farming, pets, habits, or geographic location as possible contribtory
factors in TSP pathogenesis. The etiology of TSP thus remained unclear.
A possible infectious etiology for the disease was first hypothesized three
decades ago. Because of the pathologic similarity to meningovascular syphilis
and because the geographic distribution of the disease on Jamaica is the same
as that of previous yaws endemia, treponemal associations were postulated
including atypical syphilis [Rodgers, 1965] and yaws [Montgomery, I960].
(Yaws is a non-venereal spirochetal disease caused by Treponema pertenue
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that is serologically indistinguishable from syphilis. It was previously prevalent
in many areas where TSP/HAM is now found.) Early treponemal studies
detected positive serology in greater than 60% of sera and 26.1% of CSF
samples from Jamaican patients [Rodgers, 1965], in greater than 60% of sera
and 19% of CSF samples from Colombian patients [Rodgers-Johnson et al,
1986], and in more than 42% of patients living in the Seychelles Islands [Roman
et al, 1987a]. Early serologic testing in Martinique, South Africa, and India did
not support a treponemal etiology

[Vernant et al, 1987; Cosnett et al, 1965;

Mani et al, 1969].
More recently, further testing detected Treponema pallidum antibodies in
11 of 24 sera but only 1 of 24 CSF samples from Jamaican patients
[Rodgers-Johnson et al, 1985]. Furthermore, treponemal infection prevalence
has declined in Jamaica over the past three decades while no corresponding
decrease in the prevalence of TSP has been seen [Rodgers-Johnson, 1989].
An unexplained finding was the presence of antibodies to Borrelia burgdorferi,
the etiologic agent in Lyme disease, in 44% and 24% of Seychelles and
Jamaican sera, respectively [Roman et al, 1987a; Rodgers-Johnson et al, 1986].
A viral etiology for TSP was first postulated by Montgomery and
Cruickshank in

1964 based on pathologic findings [Montgomery and

Cruickshank, 1964]. Mani further noted in 1969 that Indian TSP was similar both
clinically and histopathologically to visna-maedi lentivirus induced sheep
encephalomyelopathy [Mani et al, 1969]. In addition, although most TSP
patients' CSF samples are normal, studies from Jamaica and Martinique
detected a predominately lymphocytic pleocytosis with increased protein in
16% to 57% of patients. Despite these suggestions of infection, early virological
investigations were consistently negative [Montgomery and Cruickshank, 1964;
Rodgers, 1965; Montgomery, 1986].
The first serologic evidence of viral involvement in TSP was reported by
Greaves £i ai in 1984 who noted high antibody titers to human T-cell
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lymphotropic virus type I (HTLV-I) in one TSP patient as part of a large HTLV
serological study in the United Kingdom [Greaves et al, 1984]. However, it was
not until Gessain el al detected IgG antibodies to HTLV-I in 68% of patients with
TSP in Martinique in 1985 that HTLV-I was considered as a possible causative
agent [Gessain et al, 1985]. The significance of these results was greatly
enhanced by the detection of high titers of HTLV-I antibodies in both serum and
CSF of patients from two separate TSP foci, Jamaica and Colombia
[Rodgers-Johnson et al, 1985]. In addition, Osame filal in 1986 reported high
titers of HTLV-I antibodies in serum and CSF from 6 of 6 patients from
non-tropical southern Japan with a chronic myelopathy clinically and
histopathologically similar to TSP that they designated HAM [Osame et al,
1986].
Antibodies to HTLV-I were subsequently confirmed in the sera of a high
percentage of TSP/HAM patients from all endemic foci tested, ranging from 80%
in Martinique and the Seychelles to 92% in Jamaica to 98% in Colombia to
100% in Japan. In addition, 89% of Jamaican and 96% of Colombian TSP/HAM
patients tested in our laboratory were found to have anti-HTLV-l reactivity not
only in their serum but in their CSF as well. In contrast, the prevalence of
antibodies to HTLV-I of the general population in endemic areas ranged from
3-5% in Martinique and Jamaica to 12% in the Seychelles to 16% in southern
Japan [Montgomery, 1989] (Table 2).

Evidence for HTLV-I Infection in TSP/HAM
In addition to the strong serologic evidence etiologically associating
HTLV-I with TSP/HAM, additional evidence included:
1) Intrathecal synthesis of IgG antibodies to HTLV-I in patients as
evidenced by the presence of oligoclonal bands of HTLV-I specific IgG in CSF.
The oligoclonal band pattern against HTLV-I in CSF differed from that found in
serum. The CSF to serum albumin ratio was normal in these studies indicating
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intact blood brain barrier function [Osame et al, 1987b; Ceroni et al, 1988].
2) The presence of abnormally activated CD4+ lymphocytes with
lobulated nuclei in CSF and sera.. These cells were morphologically
indistinguishable from HTLV-I infected peripheral blood lymphocytes from ATL
patients [Osame et al, 1986a; Johnson et al, 1988; Sarin et al, 1989] (Figure 3).
3) Increased numbers in peripheral blood of large CD3+ mononuclear
cells expressing IL-2 receptor molecules consistent with HTLV-I mediated
activation of the gene encoding the alpha subunit of the IL-2 receptor [Jacobson
et al, 1988b].
4) Elevated spontaneous lymphoproliferative response in vitro of
lymphocytes from peripheral blood of patients indicating abnormal activation of
these cells [Jacobson et al, 1988b; Itoyama et al, 1988] .
5) Demonstration of HTLV-I antigens in peripheral blood lymphocytes by
immunoflourescent staining using polyclonal antiserum from a chimpanzee
infected with HTLV-I [Piccardo et al, 1988].
6) Three independent reports of virus isolation of HTLV-I or a HTLV-I like
virus from, respectively, the CSF of a HAM patient [Hirose et al, 1986],
peripheral blood of a patient with a chronic myelopathy of unknown etiology
[Defreitas et al, 1987], and CSF of a Jamaican TSP patient [Rodgers-Johnson et
al, 1988a].
Despite this evidence, isolation of HTLV-I from peripheral blood
lymphocytes or CSF mononuclear cells of patients was reported to be difficult
[Hirose et al, 1986; DeFreitas et al, 1987]. This was also the case in our
laboratory as virus was initially successfully isolated from only 1 of 30
specimens from Jamaica or Colombia.

Human T-cell Lvmphotropic Virus Type-1 (HTLV-I)
Endemicitv and Modes of Transmission
HTLV-I, the first retrovirus isolated from humans, is a type C retrovirus.
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Antibody to this rather ubiquitous virus has been detected in 3-16% of the
general population in southern Japan, the Caribbean, West Africa, and South
America. Additionally, infection has been detected in 3-6% of asymptomatic
Caribbean immigrants to the United Kingdom and in 4-5% of male
homosexuals at risk for AIDS. Testing for antibody in blood donors in the United
States has revealed only 0-0.1% positivity [Weber, 1989], while 1.9% of blood
samples assayed at the Fukuoka Red Cross Blood Center in Japan were
positive in 1983 [Okochi et al, 1984]. Following the initiation in 1986 of antibody
screening of blood samples in Japan, the seroconversion rate resulting from
transfusion decreased from 8.9% to 0.08% in Kyushu University Hospital
[Okochi and Sato, 1989].
HTLV-I is unusual in that it remains endemic in geographic foci for long
periods of time without any known vector of transmission with the exception of
man. Several modes of transmission of HTLV-I have been implicated. HTLV-I
seroconversion following blood transfusion was well demonstrated in Japan to
be mediated by viable T-cells but not by plasma [Okochi et al, 1984].
Additionally, early epidemiologic studies in Japan showed an increased
prevalence of HTLV-I in females in endemic areas [Tajima et al, 1982]. From
these studies sexual transmission with a greater frequency of transmission from
males to females than females to males was suspected. Evidence of sexual
transmission included the observation that most wives of HTLV-I positive
husbands seroconverted [Tajima et al, 1982], the demonstration of HTLV-I
infected cells in semen [Nakano et al, 1984], and the finding of increased rates
of seropositivity in sexually active homosexuals at risk for AIDS (Tedder et al,
1984; Robert-Guroff et al, 1984] and in promiscuous intravenous drug users in
comparison to nonpromiscuous matched controls [Rezza et al, 1988]. The
possibility of transmission from infected husband to wife over a ten year period
was calculated to be 60.8% in contrast to the 0.4% chance of transmission from
infected wife to husband over the same time period [Kajiyama et al, 1986].
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In addition to blood borne and sexual horizontal routes of transmission,
vertical transmission was suggested by reports of intra-familial clustering of
HTLV-I carriers [Ichimaru et al, 1979] and of an association between carrier
mothers and their children [Tajima et al, 1982]. Japanese investigators recently
demonstrated by seroepidemiologic and virologic studies that transmission from
mother to child by breast feeding is a major natural route [Hino and Doi, 1989].

Retroviral Characteristics
HTLV-I is characterized as a single stranded RNA virus that encodes a
RNA dependent DNA polymerase (reverse transcriptase). Following infection of
a susceptible cell, the reverse transcriptase "retrotranscribes" the viral RNA into
proviral DNA for integration into the host's cellular genome. Following
integration, the provirus has one of three fates: 1) to remain latent in infected
cells either thru host or viral mediated inhibition of viral transcription;

2) to

replicate resulting in viral progeny production and death of the host cell when
the host is unable to inhibit viral transcription; and 3) to induce host cell
transformation resulting in tumoral proliferation [de The, 1989].
There are three subfamilies of retroviruses. Spumavirinae have no known
associated disease. In animals, Qncornavirinae are associated with
hematological proliferations and connective tissue tumors, while Lentivirinae
are associated with neurologic and/or pulmonary diseases [de The, 1989]. No
retroviruses were known to infect humans until Gallo and his associates
developed the methodology for successfully culturing T-cells in the presence of
interleukin II (T-cell growth factor) [Morgan et al, 1976; Poiesz et al, 1980b].
Soon after this important advance, HTLV-I was isolated in 1980 by Poiesz,
Gallo, el a[ from a patient with cutaneous T-cell lymphoma (CTCL) [Poiesz et al,
1980a]. A similar retrovirus, HTLV-II, was subsequently isolated from a patient
with a T-cell variant of hairy cell leukemia [Kalyanaraman et al, 1982b]. Both
HTLV-I and HTLV-II are oncornaviruses and as such are able to induce syncytia
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and multinucleated giant cell formation in culture and transform T-lymphocytes
in vitro, in vivo infection with either of these type-C retroviruses may result in
abnormally proliferative or functionally impaired helper (CD4+) T-lymphocytes.
In contrast, HTLV-III (now named HIV-I) and HIV-II, the retroviruses
associated with the acquired immunodeficiency syndrome, are lentiviruses and
as such are genetically distinct from HTLV-I and HTLV-II and are cytopathic to
CD4+ T-lymphocytes in vitro [Desgranges et al, 1989].

Evidence for Leukemogenesis
Following initial isolations of HTLV-I from patients with CTCL, it was
demonstrated that HTLV-I could not be isolated from most CTCL patients and
that many HTLV-I isolates were from patients who did not clinically have CTCL
[Gallo, 1985]. The role of HTLV-I in human disease remained unclear until
reports from Japan implicated the virus in the pathogenesis of adult T-cell
leukemia (ATL). First described in 1977 by Takatzuki, ATL is an aggressive
leukemia of malignant helper (CD4+) T-lymphocytes that is frequently
associated with hypercalcemia and dermatologic manifestations [Uchiyama et
al, 1977]. The incidence in Japan of ATL follows a north to south gradient with
heaviest concentration on two southern islands, a pattern that is consistent with
an infectious etiology [Yoshida and Seiki, 1990].
ATL is localized in three separate areas of the world: southwestern
Japan [Uchiyama et al, 1977], the West Indies [Blattner et al, 1982], and central
Africa [Hunsmann et al, 1983]. Because HTLV-I is endemic in these same
areas, an association between HTLV-I and ATL was suspected. Sera from all
ATL patients initially tested contained antibodies to HTLV-I, and monoclonal
antibodies generated against HTLV-I proteins reacted with cultured ATL cells
[Hinuma et al, 1981; Kalyanaraman et al, 1982]. A type-C retrovirus was
isolated in 1984 from T-cell cultures of Japanese patients with adult T-cell
leukemia (ATL) that was subsequently demonstrated to be identical to HTLV-I
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isolates from the United States [Yoshida et al, 1984].
Additional evidence supporting a role for HTLV-I in leukemogenesis
followed. The virus was isolated from a Japanese-American with a T-cell
leukemia, and Caribbean born blacks who were recognized to have a
concentration of T-cell leukemias were all found to be HTLV-I positive
[Gallo,1985]. Studies of the biology and molecular virology of cell lines from
ATL patients revealed that ATL is a disease of CD4+ helper T-cells. All leukemic
cells from any individual ATL patient contained HTLV-I provirus integrated at the
same genomic site, suggesting that infection occured prior to transformation of
these cells into a lymphoproliferative clone [Yoshida et al, 1984]. Groups in
Japan and the U.S. both showed that cultured ATL cells could transform a
normal CD4+ cell line into an immortal clone [Wong-Staal and Gallo, 1985;
Yamamoto and Hinuma, 1985]. Miyoshi was then able to induce malignancies
in hamsters by inoculating cell lines transformed with HTLV-I from ATL patients
[Miyoshi et al, 1984]. Furthermore, a virus closely related to HTLV-I, simian
T-lymphotropic virus type I, was isolated from African green monkeys and found
to be associated with Simian malignant lymphoma [Hunsmann et al, 1983,
Miyoshi et al, 1982].

Biological Properties of HTLV-I Transformed Cells
Both ATL cell lines and cell lines immortalized by HTLV-I infection in vitro
are predominately CD4+ helper T-cells that spontaneously express high levels
of interleukin-2 (IL-2) receptor and grow in culture as multinucleated giant cells
with lobulated nuclei. These cultures continue to grow in the absence of IL-2 or
may require only low concentrations of exogenously added IL-2. Normal T-cell
lines, in contrast, require phytohemagglutinin activation to induce IL-2 receptor
expression, grow in culture as single cells, and require exogenously added IL-2
for continued growth [Popovic et al, 1983].
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Genomic Characteristics
HTLV-I contains a magnesium-dependent reverse transcriptase, high
molecular weight RNA, and both internal core and envelope glycoproteins. In
contrast with other mammalian type-C retroviruses, HTLV-I has a small sized
core protein (p24) and a glycosylated transmembrane protein (gp41) [Reitz et
al, 1981; Kalyanaraman et al, 1981].
Like all type-C retroviruses, the HTLV-I genome contains 5' and 3' long
terminal repeats

(LTR's) and gag, pol. and env

genes that encode viral

structural proteins, reverse transcriptase, and transmembrane glycoproteins
respectively. The aag gene encodes a 53,000 dalton polypeptide (p53) that is
proteolytically cleaved into pi 9, p24, and pi 5 internal structural proteins. The
product of the eoi gene is a magnesium dependent reverse transcriptase (RT)
that is synthesized in infected cells as a gag-pol product and detected as a
180,000-200,000 dalton polyprotein. The env gene product is a 62,000 dalton
glycosylated protein that can be cleaved into outer envelope (gp46) and
transmembrane (gp 21) proteins [Desgranges et al, 1989] (Figure 4).
HTLV-I has no known viral oncogene [Seiki et al, 1984b]. Furthermore,
although all ATL cells from an individual patient contain HTLV-I provirus
integrated at the same site, there is not a common region of proviral integration
in leukemic cells from different ATL patients [Seiki et al, 1984a]. HTLV-I thus
does not induce leukemogenesis by viral oncogenesis or insertional
mutagenesis (in which proviral integration into a specific chromosomal locus
activates an adjacent cellular oncogene- a cis-acting function). A trans-actina
viral function mediated by viral proteins was hypothesized.
HTLV-I has a genomic segment that is unique to human retroviruses.
Originally designated ial for transacting transcriptional regulation but now
termed pX, this sequence is located between the env gene and the 3' LTR and
has at least two important functions. It encodes regulatory proteins, p40*ax,
p27rex and p21, that act in trans to exert both positive and negative control on
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different stages of viral replication (Figure 4). One of these regulatory proteins,
p40tax, a|so transactivates host cell genes that encode interleukin-2 (IL-2) and
the alpha subunit of the IL-2 receptor. The alpha subunits thus synthesized are
able to combine with beta subunits normally present on the surface of T-cells to
form functional IL-2 receptors [Yoshida, 1990]. HTLV-I mediated transactivation
results in spontaneous production of IL-2 and expression of IL-2 receptors by
infected cells. It explains the lack of dependence of HTLV-I transformed cell
lines on exogenous IL-2 [Inoue et al, 1986]. Production of IL-2 and IL-2
receptors may be responsible for the early stages of ATL development [Yoshida
and Seida, 1990].
Interestingly, creation of transgenic mice by transfection with the HTLV-I
tat gene together with an associated promotor resulted in the development of
multiple mesenchymal soft tissue tumors in the mice. No transfected mice in this
murine

transgenic

model

developed

myeloneuropathy [Nerenberg et al, 1987].

either

leukemia/lymphoma

or
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PATIENTS
In the initial stage of this project, isolation of HTLV-I was attempted from
peripheral blood of TSP/HAM patients and controls from the endemic foci of
Jamaica and Tumaco, Colombia. Heparinized blood was shipped on ice from
these areas by overnight mail for attempted viral isolation. The establishment of
a successful system for isolation of HTLV-I from TSP/HAM patients coincided
with the visit to the National Institutes of Health of a family of three from Tumaco
with TSP/HAM of varying duration and clinical severity. The methodology used
to isolate virus from TSP/HAM patients is detailed as it was applied to the
members of this family.
Described here are the clinical findings and HTLV-I isolation from a
married couple and one son who have lived their entire lives in the endemic
TSP area of Tumaco on the southern Pacific coast of Colombia (Figure 5). They
were

seen

by

neurologists

in

Colombia

and

were

brought to

the

Neuroimmunology branch of the Clinical Center, the National Institutes of
Health, Bethesda, MD, in July 1987 for further evaluation.

Patient Histories
Patient 1
Patient 1, a 43-year-old man, had onset of disease twelve years earlier.
His first symptoms were itching of the soles of the feet, hip pain on rising in the
morning, nocturnal muscle cramps, occasional tremor, and numbness of the
lower limbs. He developed gradually progressive weakness of the lower limbs
over a period of seven years. He also developed urinary frequency and
urgency, impotence, and constipation.
Examination revealed no impairment of intellectual function. His cranial
nerves were normal.

Power was unimpaired in the upper limbs,

but he had

profound weakness of the lower limbs with spasticity, clonus, and bilateral
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Babinski responses. Hoffmann's sign was positive in both upper limbs, and his
abdominal reflexes were diminished. Superficial and deep sensation were
normal. He was able to walk with a spastic gait using one cane.
His previous medical history and family history were noncontributory.

Patient 2
Patient 2, the 44-year-old wife of patient 1, first presented with symptoms
of the disease eight years earlier when she was unable to expel the placenta
after child delivery. Soon thereafter she developed numbness and slowly
progressive weakness of the legs that was more pronounced on the right. More
recently, her upper limbs became fatigued with continued usage although they
were not subjectively weak. She also developed burning in the legs, polyuria,
loss of libido, and constipation.
On neurologic examination, her intellectual functioning was normal.
Cranial nerves were intact. She had a spastic paraparesis with generalized
hyperreflexia, bilateral positive Hoffmann's signs, ankle clonus, and positive
Babinski responses. In addition, she had marked impairment of vibration sense
below the second thoracic dermatome. She was able to walk with the aid of one
cane.
Her past medical history was significant for seven pregnancies with five
living children. She was admitted to a hospital 8 years earlier for headache and
abdominal pain. Two years ago she had herpes zoster affecting the
mid-thoracic region.

Patient 3
Patient 3, the 13-year-old fourth grade son of patients 1 and 2 had a
three year history of mild nocturnal cramps in his right more than his left leg and
occasional numbness of his lower limbs. He had no bowel or bladder problems.
In the past two years he had developed some photophobia and impairment of
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visual acuity but had been unaware of any decreased ability to study or to play
soccer.
On neurological examination, his intellectual function was normal, and
his cranial nerves were intact. He had hyperreflexia of all four limbs which was
more marked in the lower limbs. His power was good in the upper limbs, but he
had minimal weakness of the right lower limb and right ankle clonus. His
abdominal reflexes were brisk, and both plantar reflexes were extensor.
Sensation was normal to all modalities. He walked and ran unaided but with a
suggestion of a mild spastic gait.
There was no family history of neurologic disease. The extended family
and household contacts of these patients were without clinical evidence of
TSP/HAM.
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MATERIALS AND METHODS
Antibody

Determinations:

ELISA

and

Western

Immunoblot

Assays

Both serum and CSF from the three patients were tested for IgG
antibodies to HTLV-I using the Dupont/Biotech enzyme-linked immunosorbent
assay (ELISA) kit (Biotech Research Labs, E.l. Dupont, Wilmington, DE)
[Saxinger and Gallo, 1983]. Endpoint titrations were done on both serum and
CSF. Positive ELISA reactions were confirmed by Western immunoblot using a
commercially available kit for the detection of antibodies to the major proteins of
HTLV-I (Biotech research Labs, E.l. Dupont, Wilmington, DE). Serum and CSF
from each of the three patients were also assayed for IgM antibodies against
HTLV-I using small columns of quarternary aminoethyl-Sephadex A-50 ion
exchanger for IgM separation (Isolab Inc., Akron, OH) [Johnson and Libby,
1988]. Alkaline phosphatase and biotin-labeled goat antibodies to human IgM
were used for ELISA and western blot procedures, respectively (Kirkegaard and
Perry Laboratories, Inc., Gaithersburg, MD).

Cell Separation and Establishment of Cultures
Peripheral blood lymphocytes from the father and the mother and several
HTLV-I seronegative disease-free controls from the endemic TSP area of
Tumaco, Colombia, were separated from heparinized blood by Ficoll-Hypaque
(Pharmacia Fine Chemicals, Piscataway, NJ) density gradient centrifugation.
Peripheral blood lymphocytes from the son were obtained by leukopheresis
(supplied by Dr. Dale McFarlin). The cells were cultured by techniques similar to
those used to isolate HTLV-I from peripheral blood lymphocytes of ATL patients
[Poiesz et al, 1980b; Miyoshi et al, 1981]. Minor technical modifications included
the addition of alpha interferon and both recombinant and cell-derived
interleukin-2 to the culture medium.
Cells from all three patients were initially stimulated with 2 jig/ml
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phytohemagglutinin (Wellcome Diagnostics, Dartford, Eng]) [Nowell, 1960] for 4
days at a concentration of 1X10® cells/ml in culture medium containing an
enriched mixture of: RPMI 1640, 20% heat-inactivated fetal bovine serum, 1%
L-glutamine, 50 pg/ml gentamycin, 5 |ig/ml hydrocortisone, 400 pg/ml sheep
anti-human alpha interferon (Interferon Sciences, New Brunswick, NJ), 10%
cell-derived IL-2 (Advanced Biotechnologies, Rockville, MD) and 20 units/ml
recombinant IL-2 (Amgen, Thousand Oaks.CA) [Popovic et al, 1983].
Following stimulation, peripheral blood lymphocytes from the father, the
mother and controls were either grown independently in culture medium or
cocultivated with an equal number of phytohemagglutinin stimulated umbilical
cord blood lymphocytes; peripheral blood lymphocytes from the son were
cocultivated with cord blood lymphocytes, but were not grown independently
due to the low number of cells obtained after the leukopheresis. Cultures were
fed enough culture medium biweekly to maintain a cell density of 1X10®
cells/ml as monitored by Trypan Blue exclusion.
A small number of mononuclear cells isolated from 2 ml of cerebrospinal
fluid from the son were cocultivated with 1X10® cord blood lymphocytes. The
cocultivation was phytohemagglutinin stimulated for 4 days and then grown in
culture medium with biweekly feeding as needed. HUT-102 and HUT-78 cell
lines (obtained from Dr. Prem Sarin, Laboratory of Tumor Cell Biology, National
Cancer Institute, National Institutes of Health) were maintained as HTLV-I
positive and negative controls, respectively.

Preparation of Cord Blood Lymphocytes
Cord blood lymphocytes were separated from umbilical cord blood
(Advanced Biotechnologies, Rockville, MD) by Ficoll-Hypaque density gradient
centrifugation. Separated lymphocytes were then either grown independently
as a control culture or cocultivated with peripheral blood lymphocytes or
CSF-derived-mononuclear cells from the patients.
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Cellular Transformation: Requirement for lnterleukin-2
Cultures testing positive for HTLV-I by immunofluorescence were
assayed for transformation by monitoring growth in culture medium free of both
cell-derived and recombinant exogenous IL-2 [Popovic et al, 1983]. Growth was
determined by Trypan Blue exclusion. Transformed cultures were reassayed for
viral antigen by immunoflourescence.

Detection of the Viral Antigens bv Immunofluorescence
For detection of viral antigens by indirect immunoflourescence, cultured
cells were initially centrifuged out of culture medium, washed with phosphate
buffered saline, air dried onto 8 well Toxoplasmosis slides (2x10^ cells/well),
and fixed in methanol:acetone (1:1) for 15 min at room temperature. Fixed cells
were then absorbed for 45 minutes at room temperature with 10% normal goat
serum in phosphate buffered saline and washed

three times with complete

changes of buffered saline. After air drying, the cells were incubated at 37° C
for 30 min with either mouse monoclonal antibody to HTLV-I pi 9 or mouse
monoclonal antibody to HIV p24. The slides were rinsed for 45 min in buffered
saline/.25% Triton X-100 with 3 changes and air dried.

Flourescein

isothiocyanate labelled goat antibody to mouse immunoglobulin (IgG) (Cappel,
Cochranvile, PA) was applied for 30 min at 37° C, followed by overnight
washing in buffered saline/.25% Triton X-100. Slides were then counterstained
with 0.02% Evans blue, washed for 30 min in buffered saline, mounted, and
examined with a Zeiss flourescent microscope [Sarin et al, 1985].

Reverse Transcriptase Assay Conditions
To obtain viral pellets for reverse transcriptase testing, 2 ml of culture
supernatant was mixed with 1.0 mi of 30% polyethlene glycol 8000 and 0.2 ml
of 4M NaCI. After overnight incubation at 4° C, the mixture was spun at 2500
RPM for 30 minutes. The pellet was resuspended in 200 (il of cold buffer (50
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mM Tris.HCI, pH 7.5, 1 mM dithiothreitol, 20% glycerol, 0.35M KCI, 0.25% Triton
X-100) and vortexed. The sample was frozen at -70° C until ready for use.
To assay reverse transcriptase activity in the viral pellets, 20 jil of viral
pellet solution was added to 30 pi of reaction mixture containing 50 mM Tris.HCI
(pH 7.5), 5 mM dithiothreitol, 100 mM potassium chloride, 0.01% Triton X-100,
10 ug/ml (dT)15(A)n as template primer and [^H] deoxythymidine triphosphate,
and incubated for 1 hr at 37° C. The reaction was stopped by adding 10 pi of
yeast transfer RNA (5mg/ml) and 2 ml of 10% trichloroacetic acid solution
containing 10 mM sodium pyrophosphate. After standing in ice for at least 15
minutes, the samples were filtered on millipore filters, washed 5 times with 5%
trichloroacetic acid, washed once with 70% ethanol and dried under a heat
lamp. Dried filters were added to scintillation fluid, and radioactivity was
counted in a 6-scintillation counter [Sarin et al, 1985].

Electron Microscopy
Cell lines were prepared for electron microscopy as follows. Cultures
were centrifuged gently at 500xg at room temperature. The supernatant was
discarded and replaced with 2.5% glutaraldehyde freshly prepared in
cacodylate buffer, pH 7.4. The pellet was then processed as a solid tissue as
follows: postfixation in 1% osmiun tetroxide for 2 hours, dehydration through
graded ethanols, clearing in propylene oxide, and embedding in Embed
[Electron Microscopic Sciences, Fort Washington, PA]. Ultrathin sections were
stained with lead citrate and uranyl acetate and examined with a Phillips 300
transmission electron microscope [Liberski et al, 1988]. All electron microscopy
was performed by Dr. Pawel Liberski from our laboratory.
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RESULTS
Antibodies to HTLV-I in Serum and CSF
Serum and CSF from the three patients contained IgG antibodies against
HTLV-I as detected by ELISA.

Serum and CSF from the father showed the

highest reactivities, with endpoint titers of 1:2560 in serum and 1:128 in CSF.
The endpoint titration of antibodies to HTLV-I in the mother was 1:640 in serum
and 1:8 in CSF while in the son it was 1:320 in serum and 1:4 in CSF. Serum
from the son but not his parents contained IgM antibody against HTLV-I using
ELISA at a dilution of 1:10, indicative of a primary humoral response against the
virus. All samples were confirmed positive against HTLV-I specific proteins by
Western blot. Serum and CSF from the three family members demonstrated
antibodies against pi 9, p24, p28, p32, p36, p42, gp46 and p53.

In addition

samples from the mother and father were reactive with pi 5 (Figure 6).
Among the additional household relatives, HTLV-I antibodies were found
in the serum of the 46 year old clinically unaffected sister of patient 2 and in the
serum of her 7 year-old daughter. No other family members were positive.

Expression of Viral Antigens and Cellular Transformation
Peripheral blood lymphocytes from the father and mother, peripheral
blood lymphocyte/cord blood lymphocyte cocultivations from all three patients,
and the CSF mononuclear cell/cord blood lymphocyte cocultivation from the
son all showed positive immunofluorescence when labelled with the murine
monoclonal antibody against HTLV-I pi 9 gag protein.

In contrast to the red

negative staining demonstrated by HTLV-I negative cultures of CBL or HUT-78,
these cultures exhibited bright yellow-green flourescein isothiocyanate staining
of pi9 viral antigens in the cytoplasm of infected cells (Figure 7). HTLV-I
isolates were obtained from peripheral blood lymphocytes of the mother and
father without cocultivation with cord blood lymphocytes. In contrast, isolation of
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HTLV-I from peripheral blood lymphocytes of adult T-cell leukemia/lymphoma
patients has traditionally required cocultivation [Markham and Salahuddin,
1987]. This requirement for cocultivation differentiates HTLV-I isolated from ATL
patients from HTLV-I isolated from TSP/HAM patients. We did not attempt virus
isolation from the peripheral blood lymphocytes of the son without cocultivation
due to the few cells obtained after the patient's leukopheresis.
All HTLV-I pi 9 positive cultures from the three family members became
transformed, as defined by continued proliferation in the absence of exogenous
IL-2. In addition, the immunoflourescent reactivity of these cultures against
monoclonal antibody to HTLV pi 9 increased after selection for transformation in
exogenous IL-2 free medium. The percentage of cells expressing viral antigens
after transformation increased to as high as 85% (Figure7).
No cultures demonstrated any reactivity when assayed with a murine
monoclonal antibody against HIV p24 gag protein either before or after
transformation testing.

Control cultures (cord blood lymphocytes, peripheral

blood lymphocytes from HTLV-I seronegative controls from Tumaco, and
peripheral blood lymphocyte/cord blood lymphocyte cocultivation controls) did
not react with monoclonal antibody against HTLV-I pi 9 before transformation
testing and died soon after IL-2 was removed from the culture medium.

Ceil Growth.an.lMoi&bfllQgy
Following phytohemagglutinin stimulation, all cultures from TSP/HAM
patients and controls grew initially as predominantly single cell suspensions
and small clumps of homogeneous lymphoid cells after a week in culture. The
longevity of the single cell growth phase varied from 13 days (peripheral blood
lymphocyte/cord blood lymphocyte cocultivation of the son) to 29 days
(peripheral blood lymphocyte/cord blood lymphocyte cocultivation of the father).
A change in the culture from single cell organization to growth in large clumps,
often around a central giant cell, coincided with the expression of viral antigen
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by the cells as detected by indirect immunoflourescence.
The percentage of cells in a culture expressing viral antigen by
immunoflourescence increased in proportion to the amount of cell clumping that
could be detected micro- and macroscopically. Transformation could not be
demonstrated until the large clumps formed. These characteristics are similar to
those that have been described for HTLV-I induced transformation of umbilical
cord blood lymphocytes by T cell lines from ATL patients [Popovic et al, 1983].
In contrast to the morphologic, antigenic, and growth characteristics
exhibited by virally infected cultures following the single cell growth phase, cord
blood lymphocyte cultures and cultures of peripheral blood lymphocytes from
HTLV-I seronegative controls remained in the single cell growth phase for as
long as they could be carried in culture.

Ultrastructural Examination
Electron microscopic examination of infected cell cultures derived from
the family members revealed virus particles typical of type-C retroviruses
associated extracellularly with bizarre giant cells. Mature virions measured
80-140 nm in diameter and were indistinguishable from standard HTLV-I
viruses.

Various stages of virus maturation were seen. Initially, virus formed

crescent shaped buds at the plasma membrane. As the budding process
continued, the membrane covered cores were closed, and mature virions were
released containing electron dense nucleocapsid cores surrounded by a
smooth envelope (Figure 8).

Reverse Transcriptase Activity
Reverse transcriptase activity was assayed in all cultures. In comparison
to cultures of peripheral blood lymphocytes from HTLV-I seronegative disease
free controls all of which had radioactivity counts less than 500, cultures from
the family members had counts ranging from 1778 (CSF mononuclear cell
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cocultivation from the son) to 6426 (peripheral blood lymphocyte cocultivation
from the son). Counts from an HTLV-I infected cell line from an ATL patient
(HUT 102) were consistently greater than 25,000. The background radioactivity
count ranged from 390 to 423.
A radioactivity count of three times background was considered
evidence of viral reverse transcriptase in the culture. Using this criterion,
reverse transcriptase activity was detected in all cultures in which cells
expressed viral antigens by immunoflourescence. These levels did not change
significantly after cultures were grown in the absence of IL-2. Control cultures
had no detectable enzyme activity.
It is unclear why the reverse transcriptase levels detected in cultures from
TSP/HAM patients in this study were much lower than those detected in an ATL
derived cell line (HUT 102). Subsequent studies performed in our laboratory
detected significantly higher levels of activity in peripheral blood lymphocyte
cultures from TSP/HAM patients. The activity in these cultures increased with
time to a level comparable to that found in cell lines from ATL patients
[Rodgers-Johnson, personal communication].
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DISCUSSION
General Comments
A viral etiology has been proposed for many chronic neurological
diseases including multiple sclerosis, Alzheimer's Disease, and Parkinson’s
Disease. Essential to implicating a viral pathogen in these diseases is the
consistent isolation of virus from clinical cases. For diseases of postulated viral
origin such as multiple sclerosis, the criterion of viral isolation has not been
repeatedly fulfilled [Johnson, 1982]. In contrast, HTLV-I is etiologically
associated with TSP/HAM, and, as shown by this study, virus can be
consistently isolated from patients with this disorder.
In this investigation, methodology that was previously used to isolate
HTLV-I from ATL patients was slightly modified to isolate virus from patients with
TSP/HAM. HTLV-I was isolated from peripheral blood lymphocytes and
CSF-derived mononuclear cells of a 13-year-old boy with early TSP/HAM and
from peripheral blood lymphocytes of his 44-year-old mother and 43-year-old
father, both of whom have disease of longer duration and worse severity. All
three family members had IgG antibodies to HTLV-I in both serum and CSF, as
detected by ELISA and confirmed by western immunoblot.
Successful isolation of a retrovirus was demonstrated by the presence of
low levels of reverse transcriptase in cell culture supernatants combined with
the presence of type-C retroviral particles budding off of the surface of infected
cells as observed by electron microscopy. The retrovirus infecting these cell
cultures was shown to be HTLV-I by positive staining when assayed by indirect
immunoflourescence with a murine monoclonal antibody against the pi 9 gag
protein of HTLV-I. In addition, subsequent studies in our laboratory by
polymerase chain reaction DNA amplification showed that these isolates were
definitely HTLV-I and not HTLV-I I [Rodgers-Johnson et al, in preparation]. This
was important because HTLV-II is an oncornavirus that is structurally and
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antigenically similar to HTLV-I and may cross react with HTLV-I in some
serologic assays [Wong-Staai et al, 1985]. HTLV-II is currently not etiologically
associated with human disease.
The time in culture required to isolate virus varied inversely with the
stage of disease of the respective family members. Over double the time in
culture was required to isolate virus from the father, who first presented with
TSP in 1975, than was needed to isolate virus from the son, who just recently
developed upper motor neuron signs. The son represents an early stage of
TSP, and the possibility that virus is more readily isolated from patients in the
early stages of the disease should be further investigated. Transmission of
HTLV-I to the son was most likely vertical via breast milk [Osame et al, 1987],
but seroepidemiological studies need to be carried out to exclude other
possible modes of transmission including insect vectors.

S.iflDjiLcao£g of, the Present Finding?
This study was particularly significant for several reasons. Using
methodology very similar to that previously established in the study of ATL, it
resulted in consistent isolation of virus from TSP/HAM patients. Isolation had
previously been reported to be difficult, and only individual case reports of
successful isolation had been described [Hirose et al, 1986; DeFreitas et al,
1987]. This had also been the case in our laboratory as virus was successfully
isolated from only 1 of 30 TSP/HAM patients [Rodgers-Johnson, 1988).
However, applying the methodology that was successful in this study, our
laboratory has since isolated HTLV-I from TSP/HAM patients from Colombia,
Jamaica, and Chile [Mora et al, in preparation]; from Jamaicans with
polymyositis [Rodgers-Johnson et al, in preparation]; and from disease-free
inhabitants of an HTL'V-1 endemic focus on New Guinea [Yanigahara et al,
1990]. Additionally, there are less than 10 cases recognized worldwide to date
of patients who have had both ATL and TSP/HAM, and our laboratory has
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isolated HTLV-I from one of these cases [Lee et al, 1989].
This study was the first isolation of HTLV-I from multiple TSP/HAM
patients within the same family and the first isolation from an affected child. In
addition, the 13-year-old son was the first childhood case of TSP/HAM reported
outside of Japan. TSP/HAM had been reported in Japan in children as young
as 6 years, but until this study, no childhood cases had been described outside
of Japan, and virus had never been isolated from a child with TSP/HAM.
At the time of this investigation, TSP and HAM were thought to be
separate disorders because of differences in age distribution, climate in which
they occur, and response to corticosteroids. This study demonstrated that TSP
and HAM have similar age distributions and thus provided evidence that they
are not separate entities. The two syndromes were subsequently concluded to
be identical based on similar clinical, laboratory, and histopathological findings
[Roman and Osame, 1988].
This investigation also resulted in the first report of virally infected cells
from TSP/HAM that were transformed as defined by continued proliferation in
the absence of exogenous IL-2. HTLV-I transformed cells have previously been
characterized by the production of both IL-2 and IL-2 receptors. These cells did
not require exogenous SL-2 to proliferate.

In contrast, non-transformed cells

required exogenous IL-2 to proliferate, and these cells died when SL-2 was
removed from the culture medium [Popovic et ai, 1983]. Consistent with these
criteria for transformation, our virus infected cultures did not require exogenous
IL-2 to proliferate, and a high percentage of cells in these cultures expressed
IL-2 receptors as determined by fluorescence activated cell sorting using a
monoclonal antibody to the IL-2 receptor [Stone, personal communication].
Furthermore, removal of exogenous IL-2 from the culture medium significantly
increased the percentage of cells expressing viral antigens as determined by
indirect immunofluourescence.

It is possible that the selective death of

non-transformed cells in medium free of exogenous IL-2 enhanced the
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percentage of cells in the cultures that were virally transformed.

Further Questions
Our results raise a number of questions including:
1) What further evidence exists that HTLV-I has an etiologic role in
TSP/HAM?
2) Are the viral isolates from patients with TSP/HAM and ATL the same?
3) What is the significance of transformation relative to TSP/HAM?
4) What are the possible pathogenic mechanisms that result in ATL and
TSP/HAM?
5) Is TSP/HAM a model for other chronic nervous system disease?
6) Can HTLV-I be implicated in other disease processes?

To answer these questions, I will discuss findings that have been
described by members of our laboratory and other investigators subsequent to
this study.

Evidence for an Etioloaic Role of HTLV-I in TSP/HAM
With the isolation of HTLV-I from TSP/HAM patients, there is now
compelling evidence implicating a role for HTLV-I in the pathogenesis of
TSP/HAM. More than 40 geographic clusters of the disease have been
recognized, all in areas of HTLV-I endemicity. In each of these foci there is a
high prevalence of antibodies to HTLV-I in CSF and serum of affected patients
[Rodgers-Johnson et al,

1990]. Early reports of abnormally activated

lymphocytes with lobulated nuclei in the peripheral blood and CSF and of
oligoclonal bands with HTLV-I specificity in the CSF of TSP/HAM patients have
been confirmed repeatedly [Roman, 1990].

Additionally, the visualization by

electron microscopy of HTLV-l-like particles in spinal cord cells of a Jamaican
TSP/HAM patient was reported [Liberski et al, 1988].
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In addition to the virus isolation in this investigation, isolates were
obtained from peripheral blood and CSF of TSP/HAM patients by Jacobsen e]
ai [Jacobson et al, 1988a]. Bhagavati and colleagues subsequently detected
HTLV-I DNA in peripheral blood and CSF lymphocytes of patients with
TSP/HAM by enzymatic DNA amplification using the technique of polymerase
chain reaction [Bhagavati et al, 1988]. More recently, our laboratory detected
HTLV-I DNA in cell lines from TSP/HAM patients using in situ hybridization
[Beilke, personal communication].
This evidence strongly associates HTLV-I with TSP/HAM. However, the
mechanism of virally induced pathogenesis is not known. No animal model of
the disease exists as yet, but our laboratory has initiated experiments in this
regard in non-human primates, laboratory rodents, and rabbits.

Comparison of Isolates from TSP/HAM and ATL
It is still unclear whether the viral isolates from TSP/HAM and ATL are the
same. Established cell lines from the two diseases have the same in vitro
growth characteristics consisting of abnormally activated cells with convoluted
nuclei that express IL-2 receptors and grow in large clumps [McKhann et al,
1989]. We also found that cell lines from TSP/HAM patients will continue to
proliferate in the absence of exogenously added IL-2, a property charecteristic
of ATL cell lines. However, Jacobson ni al reported that isolates obtained by
activating T-lymphocytes using a monoclonal antibody to the T-cell receptor
combined with stimulation with exogenous IL-2 were dependent on exogenous
IL-2 for survival [Jacobson et al, 1988a].
Early DNA blotting studies reported that viral isolates from TSP/HAM and
ATL were identical [Yoshida et al, 1987], More recent work comparing the
complete DNA sequence of provirus from the two diseases reported greater
than 97% homology [Tsujimoto et al, 1988]. However, differences between
TSP/HAM isolates and prototypical HTLV-I from ATL have been detected by
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restriction mapping [Jacobson et al, 1988a; Sarin et al, 1989], and preliminary
comparison between DNA that encodes reverse transcriptase in the two
diseases suggested that up to 5 nucleotide substitutions exist [Bangham et al,
1988].
If in fact strain differences do occur, it remains to be determined whether
these differences affect the pathogenesis of TSP/HAM versus ATL or whether
they result from geographic separation of endemic foci. The theory that infection
by a single strain of HTLV-I may result in two disease processes is supported by
the recognition to date of several individuals from widely separated geographic
areas who have developed both TSP/HAM and ATL [Groopman and Ferry,
1989; Rodgers-Johnson, personal communication].

Are Cells Lines from TSP/HAM Patients Transformed?
The significance of in vitro transformation relative to TSP/HAM must be
examined. As discussed previously, our cell lines were transformed by the
criteria of expression of IL-2 receptors by HTLV-I infected cells and continued
proliferation in the absence of exogenous IL-2 [Popovic et al, 1983]. These
properties have been shown in ATL-derived cell lines to result from
transactivation of infected lymphocytes by one of the proteins encoded for by
the HTLV-I pX region, p40tax. This protein transactivates the genes for IL-2 and
for the alpha subunit of the IL-2 receptor, resulting in spontaneous production of
IL-2 and expression of IL-2 receptors [Inoue et al, 1986]. Because infected cells
produce IL-2 and express IL-2 receptors, they spontaneously proliferate in vitro
and continue to proliferate when exogenous IL-2 is removed from the cell
culture medium. In support of transactivation occuring in TSP/HAM, recent
application of the highly sensitive technique of combining splice excluded
transcription with polymerase chain reaction genomic amplification has
demonstrated greatly increased levels of messenger RNA encoding both IL-2
and the alpha subunit of the IL-2 receptor in peripheral blood lymphocytes from
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TSP/HAM patients [Greenberg et al, 1990].
Whether this

process

represents

true

transformation

requires

consideration. In contrast to ATL, a disorder in which monoclonal transformation
of infected cells results in lymphoproliferation, TSP/HAM is not a clinically
lymphoproliferative disorder. Transformation of HTLV-I infected cell lines
implies monoclonal proviral integration. In support of transformation, studies
have described monoclonal proviral integration in TSP/HAM [Gessain et al,
1989; Nakamura et al, 1989]. However, others have supported that the virus is
polyclonally integrated in this disease [Jacobson et al, 1988a; Greenberg et al,
1989]. One recent study demonstrated that viral isolation from TSP/HAM
patients produced nontransformed cell lines that died when exogenous IL-2
was removed from the culture medium [Jacobson et al, 1988a].
It is thus possible that cell lines infected with HTLV-I from TSP/HAM
patients are not transformed in vivo. They may undergo a genetic event in vitro
resulting in monoclonal proviral integration and transformation. Alternatively,
these cell lines may be polyclonally infected resulting in persistently activated
cells that spontaneously proliferate by producing IL-2 and expressing high
levels of IL-2 receptor without actually being transformed. Consistent with this
theory is the unusual increase in proliferation of unstimulated peripheral blood
lymphocytes that has been reported in TSP/HAM patients from Peru [Johnson et
al, 1988], Colombia [Jacobson et al, 1988b], and Japan [Itoyama et al, 1988].
The lymphocytes from these patients express high levels of IL-2 receptor and
spontaneously proliferate significantly more than corresponding cells from
HTLV-I seronegative controls, disease free HTLV-I seropositive carriers, or adult
T-cell leukemia/lymphoma patients [Itoyama et al, 1988].
The mechanisms underlying transformation or persistent activation in
TSP/HAM are not fully understood.

Additionally, if HTLV-I infected cells are

monoclonally transformed in vivo, why this transformation does not result in
lymphoproliferation is not clear. Further molecular genetic studies of viral
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isolates are needed to clarify these points.

PathQflenesis.Q-f-AIL and T$p/HAM
As evidence accumulates implicating HTLV-I in the etiology of TSP/HAM,
it is becoming clear that infection by this virus may result in a rapidly
progressive lymphoproliferative malignancy, a slowly progressive spastic
paraparesis, both, or neither. The factors controlling disease expression and
mechanisms of disease pathogenesis are areas of intense scrutiny.
ATL most likely results from a direct pathogenic effect of HTLV-I in
combination with other factors. The virus is monoclonally integrated and stably
present. It can transform target T-lymphocytes both in vivo and in vitro. It is
postulated that the virus acts as an inducer of ATL risk that when modified by
the appropriate host genetic factors, virally induced immunosuppressive effects,
and/or cytogenetic alterations result in progression to ATL. One theory is that
HTLV-I mediated transactivation of genes encoding IL-2 and the IL-2 receptor is
responsible for the early stage of ATL development, but that one of the above
modifying factors is required for progression to the terminally differentiated
leukemic state [Kramer and Blattner, 1989]. Evidence for this theory includes the
finding that proviral DNA integrated into ATL cells is methylated and thus not
being actively expressed [Kramer and Blattner, 1989] and the report that
expression of HTLV-I pX genes is not required for terminal differentiation of ATL
cells [Greenberg et al, 1990].
The pathogenesis of TSP/HAM is less clearly understood. Possible
disease mechanisms include direct cytopathic effects of the virus on nervous
system tissue and both humoral and cell-mediated immunopathogenic
mechanisms. In support of direct virally induced neural tissue damage, affected
patients were shown to have intrathecal evidence of HTLV-I infection [Ceroni et
al, 1988] , and virus was isolated from their CSF mononuclear cells [Jacobson
et al, 1988; McKhann et al, 1989]. In addition, electron microscopic visualization
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of unidentified spinal cord cells detected HTLV-l-like particles [Liberski et al,
1988] . HTLV-I infection of cultured glial cells was also reported [Kim et al, 1988],
but infection of cultured neurons has yet to be demonstrated. Direct neuropathic
effects of HTLV-I may be similar to the destruction of neuronal tissue that occurs
in subacute encephalomyelitis associated with human immunodeficiency virus
infection [de la Monte et al, 1987].
A variety of immune mechanisms may be involved in TSP/HAM
pathogenesis [Murphy and Blattner, 1989]. Cell mediated possibilities include:
1) activation of T-effector cells by HTLV-I infected T-helper cells resulting in
neurologic damage and 2) alteration of T-suppressor cell function by virus
infection resulting in uncontrolled T-effector cell damage. T-cell dysfunction may
also induce disease in a permissive way. Popovic showed that HTLV-I infected
cytotoxic T-lymphocytes are dysfunctional [Popovic et al, 1984]. Deficient
cytotoxic T-cell function may allow persistent infection by other pathogens,
antibodies against which may also damage myelin. This humoral molecular
mimicry could explain the postulated cofactor role of treponemal and borrelial
infections in endemic foci where a high prevalence of these infections exists
[Rodgers-Johnson et al,

1990]. An alternate humoral mechanism of

immunopathogenesis is the cross-reaction against myelin of antibodies to
HTLV-I [Rudge, 1989].
Although direct evidence for an immunopathogenic mechanism of
disease is lacking, several characteristics of HTLV-I infection in TSP/HAM
support this process. HTLV-I specific antibodies are found in the CSF of
TSP/HAM patients [Ceroni et al, 1988], and these antibodies are at much higher
titers than in patients with ATL or HTLV-I seropositive controls [Rudge et al,
1989] . The pathology of TSP/HAM is very similar to that seen in ovine visna, an
immune mediated demyelinating neuro-inflammatory disease [Mani et al, 1969].
In this disease, the lentivirus visna maedi infects sheep mononuclear cells.
Once infected monocytes mature to macrophages, viral replication occurs, and
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viral antigens are expressed on the cell surface. The resulting immune
inflammatory response results in disease pathology the severity of which can be
modified with steroids [Rudge et al, 1989]. Although HTLV-I is an oncornavirus,
a similar mechanism may be involved. The reported response of patients in
Japan and Colombia to high dose corticosteroid treatment and the less marked
inflammatory changes in pathologic specimens following this treatment both
support an immune mechanism [Rodgers-Johnson et al, 1989].
Additional disease manifestations of HTLV-I infection that are associated
with TSP/HAM also support an immunologic pathogenesis.

Systemic

manifestations of HTLV-I infection that have been found in association with
TSP/HAM include T-lymphocyte pulmonary alveolitis, uveitis, polymyositis,
Sjogren's syndrome, arthropathy, necrotizing vasculitis, lymphocytic meningitis,
and cryoglobulinemia [WHO report, 1989]. All of these processes may

be

immune mediated as a result of HTLV-I infection of T-lymphocytes.
Recent studies of HLA haplotype-linked immune responsiveness against
HTLV-I in patients with ATL or TSP/HAM support immune modification of
disease in both of these processes. Although as yet unconfirmed in other areas
of the world, Usuku slai in Japan showed that certain human lymphocyte
antigen (HLA) haplotypes associated with a high immune response to HTLV-I
were found in 70% of TSP/HAM patients, while different HLA haplotypes
associated with a low immune response to HTLV-I were found in patients with
ATL. The authors suggested that high immune responsiveness was one of the
most important factors in the development of TSP/HAM [Usuku et al, 1988].
An equally important question that remains to be answered is why so
many HTLV-I infected people from areas of viral endemia do not develop either
TSP/HAM or ATL. The lifetime risk for HTLV-I infected individuals of developing
ATL has been estimated to be 1%. This risk increases to 3% to 5% for those
infected before age 20 years [Murphy et al, 1989]. TSP/HAM has much higher
prevalence in endemic areas than does ATL, but this likely represents the much
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less rapid clinical course of TSP/HAM. Epidemiologic studies have suggested
that childhood exposure may be more important for ATL development while
adult and childhood exposure both confer risk of TSP/HAM development
[Kramer and Blattner, 1989]. Other than these observations and the HLA
immunogenetic data discussed above, little is currently known regarding factors
affecting disease development.

Is TSP/HAM a model for multiple sclerosis?
A viral etiology for multiple sclerosis (MS) has been suggested for many
years, and a number of possible agents have been proposed. Recently, the
clinical similarity between TSP/HAM and the chronic progressive form of MS
was recognized and raised the issues of whether these disorders are identical
and whether HTLV-I plays a role in MS pathogenesis. The association between
HTLV-I and MS was first reported by Koprowski and colleagues in 1985 who
described MS patients from both Sweden and the southeastern U.S. who had
antibodies against the p24 gag antigen of HTLV-I. T-cells from the CSF of these
patients contained HTLV-I RNA sequences by in Siln hybridization [Koprowski
et al, 1985]. A second report appearing in 1986 described antibodies reactive to
the pi 9 and p24 gag proteins of HTLV-I in 40% of Japanese MS patients [Ohta
et al, 1986].
Taken together, the serologic and molecular biologic evidence of HTLV-I
infection in MS patients combined with the clinical similarity between TSP and
the chronic progressive form of MS necessitated that viral isolation be
attempted from MS patients. Successful isolation would allow comparisons to
be made between HTLV-I isolates from TSP and MS. As a first step in this
process, virus isolation was attempted from 2 patients with clinical MS and
serologic evidence of HTLV-I infection as part of this study. HTLV-I infected cell
lines were not obtained from either of these patients using the same
methodology that was utilized to isolate virus from TSP/HAM patients.
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Failure to isolate virus from MS patients was not surprising considering
the growing body of information that does not support a role for prototypical
HTLV-I in MS. Poser reviewed the data concerning HTLV-I in MS pathogenesis
and concluded that it is "highly unlikely that HTLV-I can be implicated as the
etiologic agent of multiple sclerosis" [Poser, 1989]. More recently, preliminary
results from a large blinded study looking at the role of HTLV-I in MS using
polymerase chain reaction DNA amplification detected HTLV-I genomic
segments in only 14 of 1368 peripheral blood lymphocyte samples from MS
patients [Greenberg, personal communication].

HTLV-I and Other Diseases
HTLV-I has recently been associated with other disease processes
including polymyositis and malignant fibrous histiocytoma. Sera of 11 of 13
biopsy proven cases of Jamaican polymyositis were reported to have high titers
of antibodies to HTLV-I [Morgan et al, 1989]. HTLV-I infected patients with
TSP/HAM and polymyositis had been previously described [Goudreau et al,
1988; Bhagavati et al, 1988], but this report associated HTLV-I with polymyositis
alone. The authors suggested that HTLV-I be considered as a cause of
polymyositis in areas of virus endemia. This etiologic association was
supported by the recent isolation of virus from a Jamaican polymyositis patient
[Rodgers-Johnson et al, in preparation]. Further studies are needed to
determine whether this association

is significant relative to disease

pathogenesis.
A case was also reported of malignant fibrous histiocytoma in an
individual with a history of both TSP/HAM and ATL [Lee et al, 1989]. Attempts to
demonstrate HTLV-I antigen in sections of this patient's sarcoma were
unsuccessful. However, the authors concluded that this tumor may have
resulted from HTLV-I infection because it histopathologically was very similar to
the multiple mesenchymal tumors that develop in transgenic mice transfected
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with the iai gene of HTLV-I [Nerenberg et al, 1987]. Additionally, the chance of a
malignant fibrous histiocytoma occurring randomly in a patient in association
with TSP/HAM and ATL was calculated to be 1 in 101®. If this tumor did result
from HTLV-I infection, it further expands the spectrum of disease that may result
from HTLV-I infection.
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CONCLUSION
In a remarkably short period of time, a chronic neurologic disease of
strikingly high incidence in certain areas of the world that was previously an
epidemiologic mystery has been clarified. As HTLV-I is now recognized as the
probable causative agent of TSP/HAM in addition to ATL, public health
measures have begun to decrease transmission of the virus. Mandatory
screening of all blood donors has begun in Japan and is being carried out in
selected areas of the United States. In addition, recommendations against
breast feeding by infected mothers have been made although they are
impractical in many countries. The discovery that a virus known to cause
leukemia also is implicated in the development of a chronic neurologic disorder
by different pathogenic mechanisms raises the possibility that other infectious
agents may be working in unsuspected ways to result in diseases of unknown
etiology.
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Table 1. Prevalence of Neurological Signs and Symptoms in 301
TSP patients.
Sian/Svmptom
Weakness/spasticity (lower limbs)

% Affected
100

Urinary disturbance (e.g. frequency, urgency)

71

Constipation

65

Impairment of postural/vibratory sense

56

Positive jaw jerk

30

Impairment of light touch/pain sensation

28

Abnormal pupils

20

Muscle wasting

14

Visual impairment (sometimes optic atrophy)

14

Nerve deafness

9

Cerebellar signs (first noticed in upper limbs)

8

Adapted with permission from Rodgers-Johnson, 1989a
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Table 2. Prevalence of IgG Antibodies to HTLV-I in serum and/or
CSF of patients with TSP/HAM and in the general adult population
in areas of endemicity.

Endemic Reaion

% IgG Antibodies to HTLV-I
TSP/HAM patients
Population
CSF
Serum
Serum

Jamaica

89

91

3-5

Colombia

96

98

10

Martinique

100

80

4

Trinidad

87

87

4

Seychelles

—

85

12

100

100

16

Japan (Kagoshima)

Modified with permission from Rodgers-Johnson et al, 1988b.
Antibody reactivity detected by enzyme-linked immunosorbent assay (ELISA)
in all areas except Japan (gelatin particle agglutination test).
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Figure 1. Worldwide distribution of tropical ataxic neuropathy (TAN) and
tropical spastic paraparesis (TSP). Blackened areas indicate regions where a
high prevalence of HTLV-1 antibodies has been detected in TSP/HAM
patients, while hatched regions are endemic TSP/HAM foci where HTLV-1
seropositivity has not been fully tested. [Courtesy of Dr. Pamela
Rodgers-Johnson, Laboratory of Central Nervous System Studies, National
Institutes of Health].
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Figure 2. Histopathologic findings from spinal cord tissue of a 40-year-old
Jamaican woman with TSP/HAM who died of a massive pulmonary embolism
5 years after the onset of disease. The left photomicrograph illustrates
perivascular cuffing of a predominately lymphocytic infiltrate of mononuclear
cells in the meninges and scattered in the gray and white matter of the
parenchyma (hematoxylin and eosin, XI6.5). The right panel shows
prominent demyelination of the lateral column of the spinal cord (Luxol fast
blue, XI 6.5). [Courtesy of Dr. Pedro Piccardo, Laboratory of Central Nervous
System Studies, National Institites of Health].
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Figure 3. Light microscopic examination of peripheral blood from a
66-year-old Jamaican female with a 13 year history of TSP/HAM. The cell
prominently displayed is an abnormal giant lymphocyte with convoluted
rosette type nuclei. These cells, which are found in both CSF and peripheral
blood of TSP/HAM patients, are morphologically similar to HTLV-I infected
lymphocytes seen in peripheral blood of adult T-cell leukemia patients.
[Courtesy of Dr. Prem Sarin, Laboratory of Tumor Cell Biology, National
Institutes of Health].

50

LTR

POL

GAG

ENV

pX

LTR

iA i A
internal structural

envelope proteins

proteins

Figure

regulatory
proteins

4: Schematic diagram of HTLV-I
genomic structure.

51

Figure 5. Three members of a Colombian family from the endemic
TSP/HAM focus of Tumaco. The father, mother, and son have TSP/HAM of
varying clinical severity and duration, and all three have IgG antibodies to
HTLV-I in their serum and CSF. [Courtesy of Dr. Carlos Mora, Laboratory of
Central Nervous System Studies, National Institutes of Health].
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Figure 6. Western immunoblot for detection of antibodies against
polypeptides of human T-lymphotropic virus type-1 (HTLV-I). Human positive
and negative refreence sera (left) are compared with serum and
cerebrospinal fluid (CSF) of the father, mother, and son. Labelled bands
include pi 9 and p24 gag internal structural proteins, gag precursor proteins
p36 and p53, and the outer envelope glycoprotein gp46.
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Figure 7. Immunoflourescence of cultured cells from TSP/HAM patients and
controls following reaction with flourescein-labelled mouse monoclonal
antibody to HTLV-I pi9 antigen. A) Negative staining of cultured peripheral
blood lymphocytes from an HTLV-I seronegative disease free control. B)
Granular intracytoplasmic immunoflourescent staining of cocultivated
peripheral blood lymphocytes from the son. C) Eight days following removal of
exogenous interleukin-2 (IL-2) from growth medium of culture assayed in B),
immunoflourescent reactivity and the percentage of cells expressing viral
antigens has increased markedly. D) Similar staining pattern demonstrating
HTLV-I antigen in cocultivated cerobrospinal fluid mononuclear cells from the
son.
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Figure 8. Electron microscopic examination of cultured peripheral blood
lymphocytes from the mother showing: A) Extracellular mature virions that
resemble HTLV-I like type-C particles with rounded nucleoid cores
(arrowheads). B) Virion budding from the surface of infected cell (arrowhead).
C) Two virions budding from the surface of infected cells (arrowheads). Bar=
0.2 |im.
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